Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$271.19−0.54 (-0.20%)
Close on Nov 17, 2026Market cap $16.81BP/E 22.3Yield –
Ascendis Pharma A/S operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ascendis Pharma A/S's operating income for the twelve months ending Jun 30, 2026 was €266.17M. For fiscal 2025 it was -€136.27M. The highest annual figure on record is -€41.83M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€136.27M | – |
| FY2024 | Dec 31, 2024 | -€278.76M | – |
| FY2023 | Dec 31, 2023 | -€455.54M | – |
| FY2022 | Dec 31, 2022 | -€561.81M | – |
| FY2021 | Dec 31, 2021 | -€451.79M | – |
| FY2020 | Dec 31, 2020 | -€330.62M | – |
| FY2019 | Dec 31, 2019 | -€226.72M | – |
| FY2018 | Dec 31, 2018 | -€154.76M | – |
| FY2017 | Dec 31, 2017 | -€111.54M | – |
| FY2016 | Dec 31, 2016 | -€72.92M | – |
| FY2015 | Dec 31, 2015 | -€41.83M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €220.47M | – |
| Q1 FY2026 | Mar 31, 2026 | €24.81M | – |
| Q4 FY2025 | Dec 31, 2025 | €9.90M | +2483.8% |
| Q3 FY2025 | Sep 30, 2025 | €11.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -€52.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -€104.21M | – |
| Q4 FY2024 | Dec 31, 2024 | €383.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -€96.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -€133.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -€49.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -€36.61M | – |
| Q3 FY2023 | Sep 30, 2023 | -€134.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -€140.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -€143.69M | – |
| Q4 FY2022 | Dec 31, 2022 | -€147.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -€144.51M | – |
| Q2 FY2022 | Jun 30, 2022 | -€141.89M | – |
| Q1 FY2022 | Mar 31, 2022 | -€128.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -€112.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -€96.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -€117.63M | – |
| Q1 FY2021 | Mar 31, 2021 | -€124.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -€95.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -€78.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -€82.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -€73.21M | – |
| Q4 FY2019 | Dec 31, 2019 | -€64.85M | – |
| Q3 FY2019 | Sep 30, 2019 | -€54.02M | – |
| Q2 FY2019 | Jun 30, 2019 | -€51.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -€56.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -€35.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -€38.29M | – |
| Q2 FY2018 | Jun 30, 2018 | -€45.44M | – |
| Q1 FY2018 | Mar 31, 2018 | -€35.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -€31.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -€31.47M | – |
| Q2 FY2017 | Jun 30, 2017 | -€24.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -€23.56M | – |
See a number that looks wrong?